German mRNA startup SRTD completes €31.5 million seed round
German Jülich-based mRNA therapy company SRTD Biotech has completed an oversubscribed €31.5 million seed round, led by Mérieux Equity Partners and co-led by NRW.BANK and Boehringer Ingelheim Ventures; the funds will be used to advance its seRNA platform that expresses exclusively in diseased cells and LNP delivery.